A recent study that found there has been a massive increase in type 2 diabetes cases worldwide since 1990 is an indication ...

Meanwhile, Hims & Hers tackles the GLP-1 shortage with a new app; Eli Lilly releases data on tirzepatide efficacy; 23andMe faces privacy concerns; and more.

Thank you for standing by. My name is John, and I’ll be your conference operator today. At this time I would like to welcome everyone to the Allurion Third Quarter Earnings Call. All lines have been ...

With brand-name GLP-1s for obesity treatment on and off the shortage list, prescribing can get complicated. Five providers ...

A study published Wednesday suggests a surprising side effect of GLP-1 drugs such as Ozempic: they can be effective at ...

Hims & Hers Health launched a GLP-1 Supply Tracker to spotlight challenges in accessing obesity medications, addressing ...

It allows providers to follow and coach and monitor patients who are going through a variety of different weight loss interventions, whether it’s the Allurion Balloon outside the United States GLP-1s.

Hims & Hers Health, Inc. ("Hims & Hers", NYSE: HIMS), the leading health and wellness platform, today shared more data on the challenges Americans are facing when trying to access branded GLP-1 ...

Eyeing Future Approaches to GLP-1s Commenting for TCTMD ... adding that “this is a conversation that doesn’t happen enough, ...

This is just a glimpse of the GLP-1 insights available to CivicScience clients. Want to see the full picture? Let’s talk.

ATLANTA — Popular drugs like Ozempic and Wegovy are known for dramatic weight loss, but they also can potentially help with ...

As the FDA issues a new warning about aspiration across all GLP-1 weight loss drugs, doctor groups are giving new ...